Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
An analysis of the long-term activity ratios reveals a divergence between the efficiency of fixed asset utilization and the efficiency of overall asset and equity utilization between 2015 and 2019.
- Net Fixed Asset Turnover
- A consistent downward trend is observed in net fixed asset turnover, declining from 9.58 in 2015 to 8.35 in 2019. This suggests a gradual decrease in the revenue generated per unit of net fixed assets. A more pronounced decline is evident when including operating lease right-of-use assets, where the ratio dropped sharply from 8.83 in 2018 to 6.66 in 2019, indicating a significant increase in leased assets relative to revenue growth during the final period.
- Total Asset Turnover
- In contrast to fixed assets, total asset turnover demonstrates a steady improvement. The ratio remained stable at 0.11 through 2016 before rising progressively to 0.17 by 2019. This upward trajectory indicates an increasing efficiency in utilizing the company's entire asset base to generate sales.
- Equity Turnover
- Equity turnover shows a general positive trend over the five-year period. After a slight decrease from 0.20 in 2015 to 0.19 in 2016, the ratio grew consistently, reaching 0.28 by 2019. This indicates that the company has become more effective at generating revenue from its shareholders' equity.
Overall, the data indicates that while the efficiency of fixed asset employment has deteriorated—particularly regarding leased assets in the most recent year—the broader utilization of total assets and equity has improved, suggesting a shift in the asset structure or an increase in operational leverage.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Fixed Asset Turnover
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Property, plant and equipment, net | 1,926,500) | 1,787,000) | 1,785,400) | 1,611,300) | 1,573,900) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 8.35 | 8.83 | 8.93 | 9.04 | 9.58 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Net fixed asset turnover = Net revenues ÷ Property, plant and equipment, net
= 16,088,900 ÷ 1,926,500 = 8.35
2 Click competitor name to see calculations.
The analysis of long-term investment activity reveals a consistent decline in the efficiency of fixed asset utilization over the five-year period from 2015 to 2019.
- Net Revenue Trends
- Net revenues exhibited moderate fluctuations, beginning at 15,071,000 thousand USD in 2015, dipping to 14,570,600 thousand USD in 2016, and gradually recovering to 16,088,900 thousand USD by 2019. Although there was an overall increase in top-line performance, the growth was not linear and remained relatively constrained.
- Fixed Asset Expansion
- Net property, plant, and equipment showed a steady upward trajectory, increasing from 1,573,900 thousand USD in 2015 to 1,926,500 thousand USD in 2019. This represents a continuous commitment to capital expenditure and the expansion of the company's physical asset base.
- Net Fixed Asset Turnover Efficiency
- The net fixed asset turnover ratio demonstrates a persistent downward trend, falling from 9.58 in 2015 to 8.35 in 2019. This decline indicates that the growth in fixed asset investments has outpaced the growth in net revenues. Consequently, the company has become less efficient at generating sales relative to its investment in long-term physical assets, suggesting a diminishing marginal return on these capital investments over the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Allergan PLC, net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Property, plant and equipment, net | 1,926,500) | 1,787,000) | 1,785,400) | 1,611,300) | 1,573,900) | |
| Right of use asset, operating leases | 490,400) | —) | —) | —) | —) | |
| Property, plant and equipment, net (including operating lease, right-of-use asset) | 2,416,900) | 1,787,000) | 1,785,400) | 1,611,300) | 1,573,900) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 6.66 | 8.83 | 8.93 | 9.04 | 9.58 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Net revenues ÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= 16,088,900 ÷ 2,416,900 = 6.66
2 Click competitor name to see calculations.
The financial data reveals a consistent decline in the efficiency of fixed asset utilization over the five-year period from 2015 to 2019. While revenues remained relatively stable, the growth in net fixed assets, particularly a sharp increase in the final year, has led to a reduction in the revenue-generating capacity of the long-term investment base.
- Net Revenue Performance
- Revenues exhibited minor fluctuations, starting at 15.07 billion in 2015 and ending at 16.09 billion in 2019. A slight dip occurred in 2016, followed by a recovery in 2017 to 15.94 billion. For the remainder of the period, revenue growth remained marginal, indicating a plateau in top-line expansion.
- Fixed Asset Growth
- Property, plant, and equipment, including right-of-use assets, showed a steady upward trend from 1.57 billion in 2015 to 1.79 billion in 2018. A significant escalation occurred in 2019, with assets rising to 2.42 billion. This represents a substantial increase in the capital base during the final year of the analyzed period.
- Net Fixed Asset Turnover Trajectory
- The net fixed asset turnover ratio experienced a monotonic decline, falling from 9.58 in 2015 to 6.66 in 2019. From 2015 to 2018, the ratio decreased gradually from 9.58 to 8.83, suggesting that asset growth slightly outpaced revenue gains. However, a sharp contraction was observed in 2019, where the ratio dropped to 6.66. This acceleration indicates that the significant investment in fixed assets in 2019 did not yield a proportional increase in revenue, resulting in a marked decrease in asset productivity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Total Asset Turnover
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Total assets | 94,699,100) | 101,787,600) | 118,341,900) | 128,986,300) | 135,840,700) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.17 | 0.16 | 0.13 | 0.11 | 0.11 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Total asset turnover = Net revenues ÷ Total assets
= 16,088,900 ÷ 94,699,100 = 0.17
2 Click competitor name to see calculations.
Between 2015 and 2019, a consistent improvement in asset utilization efficiency is observed. While net revenues remained relatively stable with a slight upward trajectory, a substantial contraction in the total asset base resulted in a steady increase in the total asset turnover ratio.
- Net Revenues Trend
- Net revenues exhibited modest growth over the five-year period, rising from 15.07 billion US dollars in 2015 to 16.09 billion US dollars by 2019. Despite a slight dip in 2016, the top-line performance remained resilient, suggesting a stable market position and consistent revenue generation capabilities.
- Total Assets Contraction
- A significant downward trend is evident in the total asset base, which decreased from 135.84 billion US dollars in 2015 to 94.70 billion US dollars in 2019. This represents a reduction of approximately 30% of the total assets over the analyzed period, indicating potential divestitures, asset write-downs, or a strategic restructuring of the balance sheet.
- Total Asset Turnover Performance
- The total asset turnover ratio improved from 0.11 in 2015 to 0.17 in 2019. This upward trend is primarily driven by the reduction in total assets rather than aggressive revenue growth. The increase in the ratio indicates that the company generated more revenue per unit of asset held by the end of the period, reflecting enhanced operational efficiency in utilizing its remaining investment base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Equity Turnover
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Shareholders’ equity | 58,173,600) | 65,114,100) | 73,821,100) | 76,192,700) | 76,591,400) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 0.28 | 0.24 | 0.22 | 0.19 | 0.20 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Equity turnover = Net revenues ÷ Shareholders’ equity
= 16,088,900 ÷ 58,173,600 = 0.28
2 Click competitor name to see calculations.
Between 2015 and 2019, a consistent upward trend in equity turnover is observed, with the ratio increasing from 0.20 to 0.28. This improvement in the ratio is characterized by a divergence between relatively stable revenue generation and a steadily contracting equity base.
- Net Revenue Analysis
- Net revenues exhibited minimal volatility and marginal overall growth over the five-year period. Figures fluctuated from a high of 16.09 billion US dollars in 2019 to a low of 14.57 billion US dollars in 2016. The lack of substantial growth in top-line revenue suggests that the increase in turnover is not driven by operational expansion.
- Shareholders' Equity Analysis
- A significant and continuous decline in shareholders' equity is evident. The equity base decreased from 76.59 billion US dollars in 2015 to 58.17 billion US dollars in 2019. This represents a substantial reduction in the total equity held by the company, with the most pronounced decreases occurring between 2017 and 2019.
- Equity Turnover Synthesis
- The increase in equity turnover from 0.20 to 0.28 is primarily a mathematical result of the shrinking denominator (shareholders' equity) rather than an increase in the numerator (net revenues). While the ratio indicates a higher efficiency in generating revenue per unit of equity, this is attributable to a leaner capital structure rather than a surge in sales performance.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?